
$187m supports a new generation of ADC therapies
Biotechnology company Callio Therapeutics has announced its launch with the closing of a $187 million Series A financing round. Callio is focused on realising the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy. The newly formed company, with headquarters in Seattle and Singapore,… Read More
